OLMA
Olema Pharmaceuticals, Inc. NASDAQ Listed Nov 19, 2020$9.79
+2.89%
vs $9.51
Mkt Cap $854.7M
52w Low $4.02
17.9% of range
52w High $36.26
50d MA $13.50
200d MA $17.05
P/E (TTM)
—
EV/EBITDA
—
P/B
1.8x
Debt/Equity
0.0x
ROE
-34.0%
P/FCF
-5.6x
RSI (14)
18.80
ATR (14)
$0.77
Beta
2.18
50d MA
$13.50
200d MA
$17.05
Avg Volume
1.5M
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
512 2nd Street · San Francisco, CA 94107 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.51 | -0.50 | +2.0% | 16.60 | -1.7% | -9.3% | -3.3% | +2.7% | -5.9% | -0.8% | — |
| Nov 10, 2025 | AMC | -0.44 | -0.49 | -11.4% | 8.70 | -0.7% | -5.9% | -1.6% | -1.5% | +5.8% | +1.4% | — |
| Aug 11, 2025 | AMC | -0.43 | -0.51 | -18.6% | 4.57 | +7.9% | +16.2% | -0.8% | -0.2% | +4.8% | +4.5% | — |
| May 13, 2025 | AMC | -0.49 | -0.36 | +26.5% | 4.68 | +6.2% | -3.8% | +4.2% | +0.4% | +1.9% | +5.8% | — |
| Mar 18, 2025 | AMC | -0.63 | -0.51 | +19.0% | 4.14 | +10.4% | -0.7% | +0.2% | +2.7% | +2.1% | -3.0% | — |
| Nov 12, 2024 | AMC | -0.59 | -0.60 | -1.7% | 11.54 | +3.0% | -0.5% | -12.0% | -9.2% | -5.9% | +1.0% | — |
| Aug 6, 2024 | AMC | -0.54 | -0.54 | +0.0% | 13.94 | +2.2% | -9.9% | +1.4% | -7.0% | +3.0% | +2.7% | — |
| May 8, 2024 | AMC | -0.53 | -0.56 | -5.7% | 10.85 | +5.1% | -9.3% | -5.3% | -1.1% | +10.3% | -3.1% | — |
| Mar 11, 2024 | AMC | -0.49 | -0.49 | +0.0% | 13.00 | +0.2% | -6.6% | +3.0% | -7.4% | -0.2% | -4.1% | — |
| Nov 7, 2023 | AMC | -0.51 | -0.48 | +5.9% | 16.62 | +1.2% | +3.1% | -5.8% | -2.0% | -6.8% | +7.7% | — |
| Aug 8, 2023 | AMC | -0.73 | -0.49 | +32.9% | 9.46 | +1.4% | +12.1% | -4.5% | +3.6% | -1.4% | +4.6% | — |
| May 9, 2023 | AMC | -0.66 | -0.70 | -6.1% | 7.27 | -3.4% | -8.7% | +2.4% | +2.5% | -4.0% | -5.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $15.06 | $15.33 | +1.8% | -3.3% | +2.7% | -5.9% | -0.8% | -0.3% |
| Mar 18 | Goldman Sachs | Maintains | Buy → Buy | — | $15.06 | $15.33 | +1.8% | -3.3% | +2.7% | -5.9% | -0.8% | -0.3% |
| Mar 17 | Citigroup | Maintains | Buy → Buy | — | $16.60 | $16.32 | -1.7% | -9.3% | -3.3% | +2.7% | -5.9% | -0.8% |
| Mar 17 | Guggenheim | Maintains | Buy → Buy | — | $16.60 | $16.32 | -1.7% | -9.3% | -3.3% | +2.7% | -5.9% | -0.8% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.55 | $13.54 | -37.2% | -25.8% | -1.5% | -1.0% | -4.5% | -1.3% |
| Dec 12 | Citigroup | Maintains | Buy → Buy | — | $31.58 | $32.14 | +1.8% | +4.7% | +8.4% | -4.3% | -4.9% | -5.5% |
| Dec 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $30.68 | $30.22 | -1.5% | +2.9% | +4.7% | +8.4% | -4.3% | -4.9% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.68 | $30.22 | -1.5% | +2.9% | +4.7% | +8.4% | -4.3% | -4.9% |
| Dec 11 | Goldman Sachs | Maintains | Buy → Buy | — | $30.68 | $30.22 | -1.5% | +2.9% | +4.7% | +8.4% | -4.3% | -4.9% |
| Nov 21 | Goldman Sachs | Maintains | Buy → Buy | — | $22.01 | $21.49 | -2.4% | +5.3% | +8.1% | +4.1% | +7.9% | +0.7% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $8.52 | $26.46 | +210.6% | +136.4% | -3.5% | +13.3% | +5.3% | +8.1% |
| Nov 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.52 | $26.46 | +210.6% | +136.4% | -3.5% | +13.3% | +5.3% | +8.1% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $26.46 | +210.6% | +136.4% | -3.5% | +13.3% | +5.3% | +8.1% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.36 | $7.28 | -22.2% | -17.0% | +6.6% | -1.1% | -1.2% | -0.7% |
| Sep 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.47 | $6.43 | -0.6% | -2.8% | +1.0% | +30.9% | -8.8% | -1.8% |
| Aug 14 | JP Morgan | Maintains | Overweight → Overweight | — | $5.27 | $5.27 | +0.0% | -0.2% | +4.8% | +4.5% | -5.7% | +0.4% |
| Aug 12 | Citigroup | Maintains | Buy → Buy | — | $4.57 | $4.93 | +7.9% | +16.2% | -0.8% | -0.2% | +4.8% | +4.5% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.68 | $4.97 | +6.2% | -3.8% | +4.2% | +0.4% | +1.9% | +5.8% |
| May 14 | Goldman Sachs | Maintains | Buy → Buy | — | $4.68 | $4.97 | +6.2% | -3.8% | +4.2% | +0.4% | +1.9% | +5.8% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.91 | $4.93 | +0.4% | -0.4% | +3.1% | +2.4% | +2.5% | +6.2% |
| Mar 28 | JP Morgan | Maintains | Overweight → Overweight | — | $4.20 | $4.23 | +0.7% | -2.1% | -8.5% | -11.2% | -0.3% | +0.6% |
| Mar 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.14 | $4.57 | +10.4% | -0.7% | +0.2% | +2.7% | +2.1% | -3.0% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.14 | $4.57 | +10.4% | -0.7% | +0.2% | +2.7% | +2.1% | -3.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.42 | $4.37 | -1.1% | -2.0% | +4.2% | -3.1% | +0.9% | +0.9% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.23 | +0.7% | +1.4% | +5.4% | +2.7% | -4.1% | -2.0% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.41 | $8.39 | -0.2% | -20.1% | +0.4% | -4.6% | -4.7% | -4.7% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.64 | $9.74 | +1.0% | -12.8% | -20.1% | +0.4% | -4.6% | -4.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.54 | $11.89 | +3.0% | -0.5% | -12.0% | -9.2% | -5.9% | +1.0% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.91 | $11.89 | -0.2% | -1.6% | -1.5% | +2.3% | +0.4% | -1.9% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $12.56 | $12.56 | +0.0% | +1.4% | -7.0% | +3.0% | +2.7% | -4.1% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.94 | $14.24 | +2.2% | -9.9% | +1.4% | -7.0% | +3.0% | +2.7% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.94 | $14.24 | +2.2% | -9.9% | +1.4% | -7.0% | +3.0% | +2.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.76 | $11.90 | +1.2% | +19.0% | -0.5% | -4.5% | -1.2% | +3.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.17 | $10.82 | +6.4% | -3.1% | -1.9% | +1.9% | -3.3% | -1.7% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.85 | $11.40 | +5.1% | -9.3% | -5.3% | -1.1% | +10.3% | -3.1% |
| Mar 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.00 | $13.02 | +0.2% | -6.6% | +3.0% | -7.4% | -0.2% | -4.1% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $13.02 | +0.2% | -6.6% | +3.0% | -7.4% | -0.2% | -4.1% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.75 | $12.74 | -0.1% | -5.2% | -2.9% | +7.6% | -16.5% | +4.1% |
| Sep 15 | JP Morgan | Maintains | Overweight → Overweight | — | $12.15 | $12.64 | +4.0% | +6.1% | -2.5% | +0.6% | -4.4% | -0.5% |
| Sep 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.68 | $12.68 | +0.0% | -7.0% | -2.8% | +1.8% | +6.1% | -3.3% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.61 | $10.75 | +1.3% | +19.5% | -7.0% | -2.8% | +1.8% | +6.1% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $10.60 | $10.72 | +1.1% | -4.5% | +3.6% | -1.4% | +4.6% | -11.9% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $9.46 | $9.59 | +1.4% | +12.1% | -4.5% | +3.6% | -1.4% | +4.6% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.46 | $9.59 | +1.4% | +12.1% | -4.5% | +3.6% | -1.4% | +4.6% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.64 | $6.71 | +1.1% | +2.4% | +2.5% | -4.0% | -5.2% | +9.6% |
| Mar 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.76 | $4.33 | +15.2% | +3.5% | +1.0% | -0.8% | +2.1% | -4.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.76 | $4.33 | +15.2% | +3.5% | +1.0% | -0.8% | +2.1% | -4.3% |
| Feb 22 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.16 | $4.64 | +11.5% | +9.6% | -5.0% | -5.3% | -5.1% | +5.4% |
| Jun 10 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $4.34 | $4.23 | -2.5% | -0.7% | -14.8% | -8.2% | +10.1% | -7.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.60 | $4.40 | -4.3% | +1.7% | +15.0% | +0.9% | -10.3% | -7.6% |
No insider trades available.
8-K · 8.01
!! High
Olema Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Olema Pharmaceuticals entered into an agreement with Bayer to conduct a clinical trial starting in late 2026, potentially expanding its pipeline and validating its drug candidate through a major pharmaceutical partner.
May 26
8-K · 2.02
!! High
Olema Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Olema Pharmaceuticals reported quarterly earnings results; investors should review the detailed press release for operating performance, revenue trends, and management guidance on financial condition.
May 12
8-K · 1.01
!! High
Olema Pharmaceuticals, Inc. -- 8-K 1.01: Material Agreement
Olema Pharmaceuticals entered into a material agreement with KR Oyster Point II, LLC, though specific terms require additional disclosure review to assess financial implications for shareholders.
May 1
8-K · 5.02
!!! Very High
Olema Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Dr. Prakash Raman joined Olema Pharmaceuticals' board as a Class II director, expanding the company's leadership expertise effective April 28, 2026.
Apr 29
8-K
Unknown — 8-K Filing
Olema advanced its lead breast cancer candidate palazestrant through multiple clinical regimens in 2025, signaling progress toward potential commercialization that could validate the company's pipeline and justify its biotech valuation.
Mar 16
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 10,386,845 | $155M | Added | Mar 2026 |
| 2 | Janus Henderson Group Plc | 7,108,488 | $106M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,083,517 | $46M | New | Mar 2026 |
| 4 | Morgan Stanley | 1,331,606 | $33M | Reduced | Dec 2025 |
| 5 | Jennison Associates Llc | 963,997 | $24M | New | Dec 2025 |
| 6 | Defilade Capital Management, L.p. | 1,504,536 | $22M | Added | Mar 2026 |
| 7 | Woodline Partners Lp | 1,482,030 | $22M | — | Mar 2026 |
| 8 | Franklin Resources Inc | 1,218,957 | $18M | Reduced | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 1,169,421 | $17M | Added | Mar 2026 |
| 10 | Candriam S.c.a. | 679,484 | $17M | Reduced | Dec 2025 |
| 11 | Duquesne Family Office | 986,827 | $15M | New | Mar 2026 |
| 12 | Citadel Advisors Llc | 905,332 | $13M | Reduced | Mar 2026 |
| 13 | Pictet Asset Management Holding Sa | 502,568 | $13M | Reduced | Dec 2025 |
| 14 | Vivo Capital, Llc | 671,843 | $10M | New | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 593,031 | $9M | New | Mar 2026 |
| 16 | Northern Trust Corp | 569,956 | $8M | Added | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 508,706 | $8M | Reduced | Mar 2026 |
| 18 | Ubs Group Ag | 385,061 | $6M | Added | Mar 2026 |
| 19 | Silverarc Capital Management, Llc | 206,280 | $5M | Reduced | Dec 2025 |
| 20 | Qube Research & Technologies Ltd | 312,812 | $5M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$854.7M
Enterprise Value
$322.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.89x
P/B
1.78x
P/S
—
P/FCF
-5.64x
EV/EBITDA
—
Shares Out
87.0M
Financials (TTM)
Revenue
$0
Net Income
-$185.2M
EBITDA
-$184.7M
Free Cash Flow
-$146.7M
Op Cash Flow
-$146.7M
EPS Basic
$-1.87
EPS Diluted
$-2.03
EPS Forward
$-2.25
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$533.4M
Total Liab.
$54.9M
Total Equity
$478.6M
Cash
$505.4M
LT Debt
$69K
Book Value/Sh
$5.50
Debt/Equity
0.00x
Current Ratio
9.95
Quick Ratio
9.95
Returns & Growth
ROE
-34.0%
ROA
-30.4%
ROIC
-37.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+15.0%
Price Returns
2W
-4.6%
1M
-8.5%
3M
-45.5%
6M
-53.4%
12M
+149.8%
Technicals
52W High
$36.26
52W Low
$4.02
50d MA
$13.50
200d MA
$17.05
RSI (14)
18.80
ATR (14)
$0.77
Beta
2.18
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$42.50
High
$48.00
Low
$38.00
Median
$41.50
Data updated apr 26, 2026 5:16pm
· Source: financialmodelingprep.com